1 / 16

HEMOCHROMATOSIS

HEMOCHROMATOSIS. Wendy Graham, MD, CCFP Academic ½ Day November 25, 2003. Pathophysiology. Inborn error in iron metabolism Increased iron absorption from the diet Iron overload Eventual fibrosis and organ failure Cirrhosis Cardiomyopathy Diabetes Hypogonadism.

dierdra-lysaght
Download Presentation

HEMOCHROMATOSIS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HEMOCHROMATOSIS Wendy Graham, MD, CCFP Academic ½ Day November 25, 2003

  2. Pathophysiology • Inborn error in iron metabolism • Increased iron absorption from the diet • Iron overload • Eventual fibrosis and organ failure • Cirrhosis • Cardiomyopathy • Diabetes • Hypogonadism

  3. Hereditary Hemochromatosis • Autosomal recessive disorder • Hemochromatosis gene (HFE) • Most common single gene disorder • 1/250 – 1/300 white persons is homozygous for the gene mutation • 1/10 carrier for mutation • 60-93% with disorder homozygous for the mutation C282Y (a cysteine–to-tyrosine substitution) • Also C282Y/H63D compound heterozygosity

  4. Iron Overload • Net absorption of 3-4 mg/day • Accumulation of 500 to 1000 mg iron/yr • Clinical manifestations often occur after age 40 OR when stores are 15-40 g

  5. Clinical Manifestations • Influenced by • Age • Sex • Dietary iron • Alcohol • Blood loss in menstruation and pregnancy • Unknown factors • Alcohol abuse and Hepatitis C accelerate • Classic description: cutaneous hyperpigmentation and diabetes in a patient with cirrhosis

  6. Reversible Manifestations • Heart: cardiomyopathy, conduction disturbances • Liver: abdominal pain, elevated LFTs, hepatomegaly (95%) • Skin: bronzing (melanin deposition), gray pigmentation (iron deposition) • Infection (Vibrio vulnificus, Listeria monocytogenes, Pasteurella pseudotuberculosis)

  7. Irreversible Manisfestations • Liver: cirrhosis, hepatocellular carcinoma (most common cause of death) • Pituitary gland: gonadotropin insufficiency leading to secondary hypogonadism • Pancreas: diabetes mellitus (30-60%) • Thyroid: hypothyroidism • Genitalia: primary hypogonadism • Joints: arthropathy in MCPs (20-70%), pseudogout

  8. Women & Hemochromatosis • Homozygosity is as common as in men • Symptomatic disease 10x less frequent • Presentation is later in women • Why? • Physiological blood loss in women and higher iron intake in men

  9. Diagnosis • Combination of criteria • Clinical • Laboratory • Pathologic • Elevated serum transferrin saturation >45%(earliest abnormality) and an elevated serum ferritin • Caution serum ferritin = acute phase reactant • Confirmation = ‘gold standard” = liver biopsy (also defines extent of disease)

  10. Treatment • Reserved for evidence of iron overload/complications • Desferrioxamine (DFO) ineffective • Avoid iron supplements, red meat • Avoid alcohol and tobacco • Avoid handling of raw seafood • Trestment = phlebotomy

  11. Phlebotomy • Removal of 500 ml of blood • Removes 250 mg iron • Do weekly until iron depletion • Hgb < 120 • Ferritin < 50 • Transferritin saturation < 50% • 2-3 years may be required to remove >20g • Long term maintenance about once every 3 months

  12. Genetic Testing • Gene on the short arm of chromosome 6 • Point mutations C282Y and H63D • HFE gene test in adult family members of an identified case • Should replace HLA typing • Pretest counselling (insurance, employment…) • Gene testing not recommended < 18 years • Done on whole bloold sample $200 U.S.

  13. Screening • ?population screening • Looking @ WHO criteria likely cost effective • Not yet endorsed because need more information on disease burden and expression of disease • Ongoing study in Canada and U.S of 100 000 • Currently screen in patients who have: • Chronic liver disease • Signs and symptoms associated with the disease • A family history of iron overload

More Related